• Activity INFORMATION

  Overview

  Activity attendees will gain an understanding of the role of the DNA damage response (DDR) pathway in solid tumor tumorigenesis and the latest guidelines and importance of genetic testing/counseling and related treatment recommendations; then they will be guided through an appraisal of current and emerging evidence for PARP inhibitors for solid tumor management. An expert-led discussion in transcending disparities in cancer care and improving equitable access will follow, as will a review of PARP inhibitor toxicity profiles and how to effectively anticipate, prevent, and manage adverse events that may arise. After the didactic portion of the presentation, an interactive case-based presentation will provide attendees an opportunity to apply what they have learned, with an emphasis on appropriate treatment selection, toxicity management, mitigation of modifiable health disparities, and promotion of patient adherence to oral oncolytic therapy.
  

  Handouts

  • Slide Document :   AMCP Nexus - Final Handout.pdf Download

  Financial Support By

  AstraZeneca and Merck

• Learning OBJECTIVES

  Pharmacist

  Appraise current expert consensus guideline recommendations for managing solid tumor malignancies with PARP inhibitors, including evidence-based approaches for anticipating, mitigating, and managing adverse events

  Recognize healthcare disparities that result in inequitable access and identify approaches for overcoming these obstacles and improving outcomes for all patients

  Evaluate the crucial importance of genetic testing/counseling when considering PARP inhibitor therapy for patients with solid tumors

  Use a case-based approach to develop practical strategies for appropriate treatment selection, toxicity management, mitigation of healthcare disparities and inequitable access to care, and promotion of patient adherence to PARP inhibitors and other oral oncolytics, with the express goal of improving outcomes across the solid tumor landscape

  Review emerging PARP inhibitor clinical trial data in both the treatment and maintenance settings for solid tumors, and discuss how these agents continue to galvanize change across the disease management continuum

• Activity ACCREDITATION

  Activity Type

  Knowledge

  CE Broker

  20-954368

  Universal Activity Number

  Pharmacist 0798-9999-22-277-H01-P
  

  PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

  PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

  In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.

• Activity INSTRUCTION

  Faculty

  Farah  Raheem, PharmD, BCOP Clinical Pharmacy Specialist, Hematology/Oncology, Mayo Clinic Arizona

  Scott  Soefje, PharmD, MBA, BCOP, FCCP, FHOPA Director, Pharmacy Cancer Care, Mayo Clinic

  Patrick  Pilié, MD Assistant Professor, Division of Cancer Medicine, The University of Texas

This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).